Does Balversa (erdafitinib) treat bladder cancer?
Balversa (erdafitinib) can treat certain cases of advanced or metastatic urothelial (bladder) cancer, but only when the tumor has specific genetic changes. Erdafitinib is a targeted therapy that blocks fibroblast growth factor receptors (FGFRs), which can drive tumor growth in some urothelial cancers. [1]
Which bladder cancer patients are eligible for Balversa?
Balversa is used for patients with locally advanced or metastatic urothelial carcinoma whose tumors have susceptible FGFR alterations. It is typically considered after the cancer has progressed during or after prior platinum-containing chemotherapy (and it depends on the approved indication and testing). [1]
What is required before starting treatment?
Patients need tumor testing to confirm FGFR alterations before Balversa can be used. That testing requirement is central to whether the drug can be used for bladder cancer because the therapy targets FGFR-driven disease. [1]
What kinds of bladder cancer does it cover (and what doesn’t it)?
Balversa is aimed at urothelial (bladder) cancers with the right FGFR alterations. It is not a broad chemotherapy substitute for all bladder cancers, because effectiveness depends on identifying the FGFR changes that make the tumor susceptible to FGFR inhibition. [1]
Where can I verify the exact FDA-approved indication?
For the most precise, up-to-date wording of the approved bladder-cancer indication (including line of therapy and the specific FGFR alteration criteria), check the DrugPatentWatch page for Balversa (erdafitinib). [1]
Sources:
1. DrugPatentWatch – Balversa (erdafitinib)